Plant Name: Hansenia weberbaueriana
Taxonomic Information:
Plant ID: NPO2392
Plant Latin Name: Hansenia weberbaueriana
Taxonomy Genus: Hansenia
Taxonomy Family: Apiaceae
Plant External Links:
NCBI TaxonomyDB:
54724
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Unknown.
Geographical Distribution:
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| GAA; | |
| BLM; ALOX15; USP2; BRCA1; POLB; | |
| GABRR1; | |
| MAPK1; | |
| CA2; CA12; CA9; CA14; | |
| PPARA; | |
| CASP1; CASP7; | |
| AHR; TP53; | |
| KMT2A; | |
| NPC1; HTT; RAB9A; LMNA; FABP3; FABP5; FABP4; MAPT; HBB; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.089E-10 | 1.757E-06 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.116E-09 | 7.358E-06 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.367E-08 | 2.480E-05 | CA12, CA14, CA2, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-08 | 2.680E-05 | ALOX15, CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.735E-08 | 2.699E-05 | CA12, CA14, CA2, CA9, HBB |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.944E-08 | 6.470E-05 | CYP1A1, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 6.240E-08 | 6.470E-05 | AHR, CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.184E-07 | 1.121E-04 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.245E-07 | 1.130E-04 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, HBB |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.729E-07 | 1.395E-04 | FABP3, FABP4, FABP5, FFAR4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 4.527E-07 | 2.899E-04 | CYP1A1, CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 4.685E-07 | 2.915E-04 | GAA, HTT, KMT2A, MAPK1, MAPT, NPC1, PPARA, TP53, USP2 |
| BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 8.612E-07 | 4.945E-04 | BLM, BRCA1, CASP1, CASP7, FABP3, FFAR4, MAPK1, NPC1, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0006915; apoptotic process | 1.710E-06 | 7.849E-04 | AHR, BRCA1, CASP1, CASP7, HTT, KMT2A, MAPK1, POLB, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0032922; circadian regulation of gene expression | 3.238E-06 | 1.343E-03 | AHR, KMT2A, PPARA, USP2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.268E-06 | 1.343E-03 | BLM, BRCA1, CASP7, CYP1A1, CYP1B1, MAPK1, NPC1 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 4.028E-06 | 1.566E-03 | AHR, ALOX15, BRCA1, CA2, CYP1A1, CYP1B1, FABP5, GAA, HTT, KMT2A, LMNA, MAPK1, POLB, PPARA, SMN1, SMN2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.811E-06 | 2.109E-03 | CYP1A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, NPC1 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 7.162E-06 | 2.476E-03 | BLM, BRCA1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.727E-06 | 2.588E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 7.956E-06 | 2.625E-03 | AHR, CYP1A1, CYP1B1, HBB, MAPK1, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.026E-05 | 3.147E-03 | CYP1A1, CYP1B1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.329E-05 | 3.965E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 1.462E-05 | 4.237E-03 | BRCA1, CYP1B1, HBB, MAPT, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.069E-08 | 2.938E-06 | CA12, CA2, CA9, CA14 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.652E-06 | 1.173E-04 | CYP2C9, CYP2D6, ALOX15, MAPK1, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 8.806E-06 | 3.126E-04 | CYP2C9, CYP2D6, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 7.031E-06 | 3.126E-04 | FABP3, FABP4, FABP5, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.399E-05 | 3.973E-04 | CYP2C9, CYP1A1, CYP1B1, CYP2C19 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.138E-04 | 2.309E-03 | CASP7, LMNA, MAPK1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.895E-05 | 4.485E-04 | CYP2C9, ALOX15, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.883E-04 | 3.342E-03 | CYP2C9, ALOX15, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.586E-04 | 4.080E-03 | CYP2C9, CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 3.308E-04 | 4.698E-03 | CASP7, CASP1, MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TP53; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TP53; CA9; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| NA: NA | HIV infections | NA | AHR; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
